NCT00003126
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
PHASE3
COMPLETED
NCT00003126
INTERVENTIONAL
A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma
The purpose of this study is to assess the efficacy of post-operative high-dose bolus interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).
Inclusion Criteria
* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate organ function as defined by a white blood cell (WBC) count of 4,000/L; a platelet count of 100,000/L; a Hemoglobin level of 10 g/dL; a serum creatinine of 1.5 mg/dL or creatinine clearance of 60 mL/min; and a direct bilirubin level of 1.5 mg/dL.
* Forced expiratory volume at 1 second more than 2.0 L or 75% of predicted for height and age from pre-enrollment pulmonary function testing.
* No history or evidence of cardiac disease on ECG
* No prior systemic treatment for RCC, but patients may have received prior locoregional radiation therapy to solitary resectable metastases, which must have undergone surgical resection before enrollment.
* No prior history of invasive malignancy in the past 5 years
* Human immunodeficiency virus (HIV) negative
* Female patients must not be pregnant or planning to become pregnant
Exclusion criteria
• Age younger than 16
Kidney Cancer
- TREATMENT
-
- Type: DRUG
- Name: Interleukin-2
- Description: High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
- Arm Group Labels: Interleukin-2 (IL-2)
- Loyola University